Results 81 to 90 of about 13,707 (310)

Clinical Characteristics of Difficult‐To‐Treat Allergic Bronchopulmonary Aspergillosis and Its Prediction Score

Allergy, EarlyView.
A retrospective cohort of newly diagnosed treatment‐naive patients with ABPA in Japan who were followed up for up to 3 years after the primary diagnosis was analyzed to explore the clinical remission rate and clinical characteristics of ABPA resistant to standard treatment or prone to exacerbation during/after treatment.
Jun Tanaka, Tsuyoshi Oguma, Takashi Ishiguro, Hirokazu Taniguchi, Teruaki Nishiuma, Hiroki Tateno, Hisako Matsumoto, Naoki Koshimizu, Yutaka Ito, Kazuto Matsunaga, Hidekazu Matsushima, Yoshitaka Uchida, Koshi Yokomura, Hirotaka Yasuba, Junko Suzuki, Shigeaki Hattori, Naoki Okada, Katsuyoshi Tomomatsu, Koichiro Asano, on behalf of ABPM Research Program   +19 more
wiley   +1 more source

May mepolizumab used in asthma correct subfertility?

Annals of Medicine, 2021
İntroduction Asthma is one of the most common chronic airway disease among reproductive period of women. Chronic inflammation in asthma, eosinophilia, high steroid treatment and uncontrolled asthma may cause infertility by affecting the reproductive ...
Guzin Ozden, Pelin Pınar Deniz
doaj   +1 more source

Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? [PDF]

, 2014
The authors acknowledge the medical writing assistance received from Sam Yarwood, PhD, of Complete HealthVizion, in the form of literature searches and preparation and revision of the draft manuscript.Peer reviewedPublisher ...
Fromer, Leonard, Kaplan, Alan, Price, David, Román-Rodríguez, Miguel, van der Molen, Thys   +4 more
core   +4 more sources

Two‐Year Data of Tapered Dupilumab Shows High Effectiveness in CRSwNP With NSAID‐Exacerbated Respiratory Disease

Allergy, EarlyView.
Two‐year data of tapered dupilumab shows high effectiveness in CRSwNP with NSAID‐exacerbated respiratory disease. We assessed whether dupilumab is equally effective in CRSwNP with NSAID‐exacerbated respiratory disease (N‐ERD) patients as in CRSwNP patients without N‐ERD (CRSwNP‐NOS; not otherwise specified).
H. B. E. Elzinga, J. J. Otten, M. E. Cornet, A. B. Rinia, R. J. L. Van Der Lans, W. J. Fokkens, S. Reitsma, PolyREG Consortium, F. C. A. Timmer, M. E. Cornet, A. B. Rinia, I. J. Kleiss, I. Krebbers, G. F. J. P. M. Adriaensen, L. B. L. Benoist, D. R. Hoven, S. Reitsma, W. J. Fokkens   +17 more
wiley   +1 more source

Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST)

Advances in Therapy
Introduction The Nucala Effectiveness Study (NEST) assessed the effectiveness of mepolizumab in patients with severe asthma (SA) in countries previously underrepresented in real-world studies.
R. Al-Lehebi, Mona Al Ahmad, V. N. Maturu, Alejandra Galeano Mesa, B. Mahboub, E. Garcia, Patricia Fernandez, Claudia Soares, Gabriela Abreu, Debora dos Santos, Juliana Queiroz, Alejandro Raimondi, M. Laucho-Contreras, S. Noibi, Gur Levy, S. Bavbek   +15 more
semanticscholar   +1 more source

Clinical and Biological Remission With Tezepelumab: The Real‐World Response in Severe Uncontrolled Asthma

Allergy, EarlyView.
This study analyzed the clinical and biomarker data from 175 adults with severe asthma treated with the anti‐TSLP monoclonal antibody tezepelumab. Following tezepelumab initiation, the exacerbation rate decreased, with 59% of patients remaining exacerbation‐free at 1 year. Asthma symptom control as measured by ACQ‐6 significantly improved after 4 weeks
Jessica Gates, Faizan Haris, Francesca Cefaloni, Paniz Khooshemehri, Linda Green, Mariana Fernandes, Louise Thomson, Cris Roxas, Jodie Lam, Grainne d'Ancona, Alexandra M. Nanzer, Jaideep Dhariwal, David J. Jackson   +12 more
wiley   +1 more source

Real-Life Evidence of Mepolizumab Treatment in Chronic Rhinosinusitis with Nasal Polyps: A Multicentric Study

Journal of Clinical Medicine
Background: The introduction of biological drugs in the management of chronic rhinosinusitis with nasal polyps (CRSwNP) is allowing new and increasingly promising therapeutic options.
C. Cavaliere, A. Loperfido, A. Ciofalo, Loreta Di Michele, E. Begvarfaj, G. Bellocchi, Marcella Bugani, Marco de Vincentiis, Antonio Greco, S. Millarelli, Michaela Plath, Eleonora Sculco, S. Masieri   +12 more
semanticscholar   +1 more source

Anaphylaxis to three humanized antibodies for severe asthma: a case study

Allergy, Asthma & Clinical Immunology, 2020
Background Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare. Case presentation We report the case
Koichi Jingo, Norihiro Harada, Toshihiko Nishioki, Masahiro Torasawa, Tomoko Yamada, Tetsuhiko Asao, Haruhi Takagi, Tomohito Takeshige, Jun Ito, Kazuhisa Takahashi   +9 more
doaj   +1 more source

Estudio de utilización de omalizumab y mepolizumab en asma refractaria grave [PDF]

, 2018
Introducción. En los últimos años, se han comercializado diferentes fármacos biológicos dirigidos a dianas específicas del asma, como el omalizumab y mepolizumab.
López Cárdenas, Mª Teresa
core  

Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity‐matched cohort study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This large‐scale, propensity‐matched retrospective cohort study provides evidence that dupilumab treatment during pregnancy is not associated with an elevated risk of maternal adverse pregnancy outcomes (APOs). By utilizing real‐world data, it contributes critical insights into dupilumab's safety profile in pregnant women, addressing a crucial gap in ...
Sophie L. Preuß, Katja Bieber, Artem Vorobyev, Andreas Recke, Eva Lotta Moderegger, Henner Zirpel, Evelyn Gaffal, Diamant Thaçi, Khalaf Kridin, Ralf J. Ludwig   +9 more
wiley   +1 more source